151 related articles for article (PubMed ID: 37176048)
21. Nuclear and cytoplasmic c-myc staining in endometrial carcinoma and their relationship to survival.
Geisler JP; Geisler HE; Manahan KJ; Miller GA; Wiemann MC; Zhou Z; Crabtree W
Int J Gynecol Cancer; 2004; 14(1):133-7. PubMed ID: 14764041
[TBL] [Abstract][Full Text] [Related]
22. MiR-101 reduces cell proliferation and invasion and enhances apoptosis in endometrial cancer via regulating PI3K/Akt/mTOR.
Zhang S; Wang M; Li Q; Zhu P
Cancer Biomark; 2017 Dec; 21(1):179-186. PubMed ID: 29081412
[TBL] [Abstract][Full Text] [Related]
23. Nuclear localization of beta-catenin in normal and carcinogenic endometrium.
Nei H; Saito T; Yamasaki H; Mizumoto H; Ito E; Kudo R
Mol Carcinog; 1999 Jul; 25(3):207-18. PubMed ID: 10411147
[TBL] [Abstract][Full Text] [Related]
24. Nuclear receptor 4A1 (NR4A1) antagonists induce ROS-dependent inhibition of mTOR signaling in endometrial cancer.
Mohankumar K; Li X; Sridharan S; Karki K; Safe S
Gynecol Oncol; 2019 Jul; 154(1):218-227. PubMed ID: 31053403
[TBL] [Abstract][Full Text] [Related]
25. Could E-Cadherin and CD10 Expression be Used to Differentiate Between Atypical Endometrial Hyperplasia and Endometrial Carcinoma?
Youssef MY; Mohamed MA
Int J Gynecol Pathol; 2019 Mar; 38(2):128-137. PubMed ID: 30726192
[TBL] [Abstract][Full Text] [Related]
26. Progesterone inhibition of Wnt/beta-catenin signaling in normal endometrium and endometrial cancer.
Wang Y; Hanifi-Moghaddam P; Hanekamp EE; Kloosterboer HJ; Franken P; Veldscholte J; van Doorn HC; Ewing PC; Kim JJ; Grootegoed JA; Burger CW; Fodde R; Blok LJ
Clin Cancer Res; 2009 Sep; 15(18):5784-93. PubMed ID: 19737954
[TBL] [Abstract][Full Text] [Related]
27. Loss of inhibitory insulin receptor substrate-1 phosphorylation is an early event in mammalian target of rapamycin-dependent endometrial hyperplasia and carcinoma.
McCampbell AS; Harris HA; Crabtree JS; Winneker RC; Walker CL; Broaddus RR
Cancer Prev Res (Phila); 2010 Mar; 3(3):290-300. PubMed ID: 20179297
[TBL] [Abstract][Full Text] [Related]
28. Evolution in endometrial cancer: evidence from an immunohistochemical study.
Vandenput I; Trovik J; Leunen K; Wik E; Stefansson I; Akslen L; Moerman P; Vergote I; Salvesen H; Amant F
Int J Gynecol Cancer; 2011 Feb; 21(2):316-22. PubMed ID: 21734474
[TBL] [Abstract][Full Text] [Related]
29. STAR and AKR1B10 are down-regulated in high-grade endometrial cancer.
Sinreih M; Štupar S; Čemažar L; Verdenik I; Frković Grazio S; Smrkolj Š; Rižner TL
J Steroid Biochem Mol Biol; 2017 Jul; 171():43-53. PubMed ID: 28232277
[TBL] [Abstract][Full Text] [Related]
30. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
[TBL] [Abstract][Full Text] [Related]
31. miR-205 inhibits cell growth by targeting AKT-mTOR signaling in progesterone-resistant endometrial cancer Ishikawa cells.
Zhuo Z; Yu H
Oncotarget; 2017 Apr; 8(17):28042-28051. PubMed ID: 28427207
[TBL] [Abstract][Full Text] [Related]
32. Expression of CD44 variant 6 and its prognostic value in benign and malignant endometrial tissue.
Kansu-Celik H; Gungor M; Ortac F; Kankaya D; Ensari A
Arch Gynecol Obstet; 2017 Aug; 296(2):313-318. PubMed ID: 28620808
[TBL] [Abstract][Full Text] [Related]
33. MRP4 sustains Wnt/β-catenin signaling for pregnancy, endometriosis and endometrial cancer.
Chen JJ; Xiao ZJ; Meng X; Wang Y; Yu MK; Huang WQ; Sun X; Chen H; Duan YG; Jiang X; Wong MP; Chan HC; Zou F; Ruan YC
Theranostics; 2019; 9(17):5049-5064. PubMed ID: 31410201
[No Abstract] [Full Text] [Related]
34. Subnuclear distribution of progesterone receptors A and B in normal and malignant endometrium.
Arnett-Mansfield RL; DeFazio A; Mote PA; Clarke CL
J Clin Endocrinol Metab; 2004 Mar; 89(3):1429-42. PubMed ID: 15001645
[TBL] [Abstract][Full Text] [Related]
35. Investigations on the mechanism of progesterone in inhibiting endometrial cancer cell cycle and viability via regulation of long noncoding RNA NEAT1/microRNA-146b-5p mediated Wnt/β-catenin signaling.
Huang X; Zhong R; He X; Deng Q; Peng X; Li J; Luo X
IUBMB Life; 2019 Feb; 71(2):223-234. PubMed ID: 30452118
[TBL] [Abstract][Full Text] [Related]
36. BAG-1 expression in normal endometrium, endometrial hyperplasia and endometrial cancer.
Song JY; Kim JW; Lee JK; Lee NW; Yeom BW; Kim SH; Lee KW
Acta Obstet Gynecol Scand; 2008; 87(8):862-7. PubMed ID: 18704778
[TBL] [Abstract][Full Text] [Related]
37. The prognostic value of semiquantitative nuclear grading in endometrial carcinomas.
Hachisuga T; Kawarabayashi T; Iwasaka T; Sugimori H; Kamura T; Tsuneyoshi M
Gynecol Oncol; 1997 Apr; 65(1):115-20. PubMed ID: 9103400
[TBL] [Abstract][Full Text] [Related]
38. Knocking down FAM83B inhibits endometrial cancer cell proliferation and metastasis by silencing the PI3K/AKT/mTOR pathway.
Lin Q; Chen H; Zhang M; Xiong H; Jiang Q
Biomed Pharmacother; 2019 Jul; 115():108939. PubMed ID: 31079003
[TBL] [Abstract][Full Text] [Related]
39. Metformin is associated with reduced cell proliferation in human endometrial cancer by inbibiting PI3K/AKT/mTOR signaling.
Zhao Y; Sun H; Feng M; Zhao J; Zhao X; Wan Q; Cai D
Gynecol Endocrinol; 2018 May; 34(5):428-432. PubMed ID: 29182407
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of overexpression of p53 in uterine endometrioid adenocarcinomas with an analysis of nuclear grade.
Urabe R; Hachisuga T; Kurita T; Kagami S; Kawagoe T; Matsuura Y; Shimajiri S
J Obstet Gynaecol Res; 2014 Mar; 40(3):812-9. PubMed ID: 24246002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
